Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Corman

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
The Journal of Urology|August 10, 2015
Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based ScreeningJohn S Banerji, Erika M Wolff, John D Massman, et al.
Cancer Cytopathology|October 28, 2016
Cytologic persistence of malignant cells after transurethral resection of bladder tumors: Implications for concomitant manipulation of the urinary tract at the time of endoscopic resectionLiam C Macleod, Khanh N Pham, S Nicholas Agoff, et al.
Urology|March 17, 2018
Evolution of the Ureteral Stent: The Pivotal Role of the Gibbons Ureteral CatheterRyan P Donahue, Andrew W Stamm, Robert P Gibbons, et al.
The Canadian Journal of Urology|February 28, 2007
Experience improves staging accuracy of endorectal magnetic resonance imaging in prostate cancer: what is the learning curve?Kalyan C Latchamsetty, Lester S Borden, Christopher R Porter, et al.
The Journal of Urology|December 21, 2012
An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancerRobert C Flanigan, Anthony J Polcari, Neil D Shore, et al.
Urology|July 31, 2013
Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancerTomasz M Beer, Paul F Schellhammer, John M Corman, et al.
Cancer|July 23, 2008
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancerCelestia S Higano, John M Corman, David C Smith, et al.
The Canadian Journal of Urology|August 24, 2017
A decision aid versus shared decision making for prostate cancer screening: results of a randomized, controlled trialAndrew W Stamm, John S Banerji, Erika M Wolff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancerTomasz M Beer, Guy T Bernstein, John M Corman, et al.
The Journal of Clinical Endocrinology and Metabolism|March 28, 2013
Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivationJames P Dean, Cynthia C Sprenger, Junxiang Wan, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
The Journal of Urology|August 10, 2015
Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based ScreeningJohn S Banerji, Erika M Wolff, John D Massman, et al.
Cancer Cytopathology|October 28, 2016
Cytologic persistence of malignant cells after transurethral resection of bladder tumors: Implications for concomitant manipulation of the urinary tract at the time of endoscopic resectionLiam C Macleod, Khanh N Pham, S Nicholas Agoff, et al.
Urology|March 17, 2018
Evolution of the Ureteral Stent: The Pivotal Role of the Gibbons Ureteral CatheterRyan P Donahue, Andrew W Stamm, Robert P Gibbons, et al.
The Canadian Journal of Urology|February 28, 2007
Experience improves staging accuracy of endorectal magnetic resonance imaging in prostate cancer: what is the learning curve?Kalyan C Latchamsetty, Lester S Borden, Christopher R Porter, et al.
The Journal of Urology|December 21, 2012
An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancerRobert C Flanigan, Anthony J Polcari, Neil D Shore, et al.
Urology|July 31, 2013
Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancerTomasz M Beer, Paul F Schellhammer, John M Corman, et al.
Cancer|July 23, 2008
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancerCelestia S Higano, John M Corman, David C Smith, et al.
The Canadian Journal of Urology|August 24, 2017
A decision aid versus shared decision making for prostate cancer screening: results of a randomized, controlled trialAndrew W Stamm, John S Banerji, Erika M Wolff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancerTomasz M Beer, Guy T Bernstein, John M Corman, et al.
The Journal of Clinical Endocrinology and Metabolism|March 28, 2013
Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivationJames P Dean, Cynthia C Sprenger, Junxiang Wan, et al.
Pageof 4